CliffBio
small molecule

SORILUX

CALCIPOTRIENE

Loss of exclusivityMay 2028latest FDA-listed patent expiry
CompanyMayne Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameSORILUX
Active ingredientCALCIPOTRIENE
Strength0.005%
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalOctober 2010
Marketing statusRX

Listed patents

PatentExpiresType
8263580May 2028product
8629128May 2026product

More from Mayne Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SORILUX patent cliff — loss of exclusivity May 2028 | CliffBio